Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

108.24USD
14 Dec 2017
Change (% chg)

$0.04 (+0.04%)
Prev Close
$108.20
Open
$108.15
Day's High
$109.52
Day's Low
$107.95
Volume
5,353,801
Avg. Vol
6,219,831
52-wk High
$147.17
52-wk Low
$94.55

Latest Key Developments (Source: Significant Developments)

Celgene Corp says on August 10, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021
Thursday, 10 Aug 2017 01:39pm EDT 

Aug 10 (Reuters) - Celgene Corp :Celgene Corp - on August 10, 2017, co issued $500 million aggregate principal amount of 2.250% senior notes due 2021 - SEC filing.  Full Article

Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia
Tuesday, 1 Aug 2017 11:30am EDT 

Aug 1 (Reuters) - Agios Pharmaceuticals Inc :FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation.  Full Article

FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia
Tuesday, 1 Aug 2017 11:16am EDT 

Aug 1 (Reuters) - U.S. FDA::U.S. FDA-Approved Idhifa (Enasidenib) for treatment of adult patients with relapsed/refractory Acute Myeloid Leukemia (AML) with specific genetic mutation.U.S. FDA - granted approval of Idhifa to Celgene corporation, granted approval of the realtime IDH2 assay to Abbott Laboratories.U.S. FDA-Idhifa approved for use with companion diagnostic realtime IDH2 assay which is used to detect specific mutations in IDH2 gene in AML patients.FDA-Prescribing information for Idhifa includes boxed warning, adverse reaction called Differentiation Syndrome can occur,can be fatal if not treated.  Full Article

Celgene International Sàrl announces results from phase 2a SLE-001 trial evaluating CC-220
Wednesday, 14 Jun 2017 07:30am EDT 

June 14 (Reuters) - Celgene International Sàrl::Announced results from phase 2a SLE-001 trial evaluating CC-220, co's investigational, oral immunomodulatory compound.Most common adverse events in trial were nausea, diarrhea and maculopapular rash.No opportunistic infections or other systemic infections were reported in any CC-220 dose groups in trial.Serious adverse events were reported in two patients in two highest CC-220 doses combined and in two patients in placebo group.  Full Article

Celgene announces positive results from radiance
Monday, 22 May 2017 07:30am EDT 

May 22 (Reuters) - Celgene Corp : :Celgene announces positive results from radiance, the second pivotal phase III trial of oral ozanimod in patients with relapsing multiple sclerosis.Celgene announces positive results from radiance, the second pivotal phase iii trial of oral ozanimod in patients with relapsing multiple sclerosis.Says study met primary endpoint.Celgene Corp says new drug application submission to U.S. Food and Drug Administration planned by end of 2017.Celgene Corp says safety and tolerability consistent with prior phase II and III studies in the study.Says further analyses of radiance trial are ongoing.Says plan to begin submitting global registration dossiers by end of year.Celgene Corp says both doses of ozanimod demonstrated statistically significant reductions in brain atrophy compared to Avonex in each phase III trial.  Full Article

Celgene Corp Q1 earnings per share $1.16
Thursday, 27 Apr 2017 07:27am EDT 

April 27 (Reuters) - Celgene Corp :Celgene reports first quarter 2017 operating and financial results.Q1 revenue rose 18 percent to $2.96 billion.Q1 earnings per share $1.16.Celgene corp - raising 2017 eps guidance.Celgene corp - positive phase ii stepstone data with ozanimod in crohn's disease; phase iii trial initiation planned by year-end.Q1 earnings per share view $1.63, revenue view $3.04 billion -- Thomson Reuters I/B/E/S.Celgene corp - revlimid sales for q1 increased 20 percent to $1,884 million.Celgene corp - sees fy gaap diluted eps $5.95 to $6.29.Celgene corp - abraxane sales for q1 were $236 million, a 5 percent increase year-over-year.Celgene corp - sees fy adjusted diluted eps $7.15 to $7.30.Celgene corp - sees fy adjusted operating margin approximately 57.0%.Celgene corp sees 2017 gaap operating margin approximately 46.0 percent.Celgene corp - fy total revenue guidance unchanged.Fy2017 earnings per share view $7.22, revenue view $13.26 billion -- Thomson Reuters I/B/E/S.  Full Article

Alliqua Biomedical says co and Celgene entered into side letter agreement
Wednesday, 15 Mar 2017 03:16pm EDT 

Alliqua Biomedical Inc : On March 13, 2017, co and Celgene entered into a side letter agreement - sec filing . co, chairman Jerome Zeldis entered into side letter agreement; Zeldis to conditionally waive MFN adjustment in securities purchase deal . Celgene agreed to waive MFN adjustment in spa to extent MFN adjustment would cause Celgene to own in excess of 19.9% of co's common stock Further company coverage: [ALQA.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Celgene & Agios collaborates with Abbott to develop diagnostic tests for leukemia
Wednesday, 12 Oct 2016 07:49am EDT 

Abbott Laboratories : Celgene and Agios announce collaborations with Abbott for diagnostic identification of IDH mutations in AML . Celgene - companion diagnostic technology to be utilized with Enasidenib, AG-120 development programs for relapsed/refractory acute myeloid leukemia .Celgene-Agreements with abbott to develop,commercialize companion diagnostic tests on Abbott's M2000 realtime system to identify IDH mutations in AML.  Full Article

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 06:23am EDT 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

Celgene reports Q2 GAAP earnings per share $0.75
Thursday, 28 Jul 2016 07:30am EDT 

Celgene Corp : Celgene reports second quarter 2016 operating and financial results . Q2 adjusted earnings per share $1.44 . Q2 revenue $2.754 billion versus I/B/E/S view $2.7 billion . Q2 GAAP earnings per share $0.75 . Q2 earnings per share view $1.38 -- Thomson Reuters I/B/E/S . Abraxane sales for Q2 were $249 million, a 2 percent increase year-over-year . Sees 2016 adjusted diluted EPS $5.70 to $5.75 . Sees 2016 revlimid net sales about $6.8 billion . FY2016 earnings per share view $5.70, revenue view $11.01 billion -- Thomson Reuters I/B/E/S . 2016 net product sales guidance for Pomalyst/Imnovid, Abraxane and Otezla remain unchanged . 2016 guidance updated: revlimid and total net product sales; EPS . Sees 2016 adjusted operating margin approximately 54.0% . Sees 2016 GAAP diluted eps $3.82 to $4.05 .Sees 2016 total net product sales about $11 billion.  Full Article

US STOCKS-Wall St ends higher with help from tech, energy

* Cryptocurrency related stocks bounce after bitcoin futures debut